Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar;23(3):475-480.
doi: 10.1111/jch.14188. Epub 2021 Feb 4.

Hypertension and chronic kidney disease in Asian populations

Boon Wee Teo  1 , Gek Cher Chan  2 , Christopher Cheang Han Leo  2 , Jam Chin Tay  3 , Yook-Chin Chia  4   5 , Saulat Siddique  6 , Yuda Turana  7 , Chen-Huan Chen  8   9   10 , Hao-Min Cheng  8   9   10   11 , Satoshi Hoshide  12 , Huynh Van Minh  13 , Guru Prasad Sogunuru  14   15 , Tzung-Dau Wang  16   17 , Kazuomi Kario  12
Affiliations
Review

Hypertension and chronic kidney disease in Asian populations

Boon Wee Teo et al. J Clin Hypertens (Greenwich). 2021 Mar.

Abstract

The countries of Asia are home to multiple ethnicities. There are ethnic differences in diet, culture, and attitudes towards health screening, access to care, and treatment of chronic diseases. Chronic kidney disease (CKD) and end-stage kidney disease (ESKD) have rising incidence and prevalence due to increased affliction with non-communicable diseases of diabetes and hypertension. To prevent the expensive complications of ESKD, one of the most important risk factors to control is hypertension in patients with CKD. We performed a narrative review on the prevalence of CKD in patients with hypertension, the prevalence and control of hypertension in patients with CKD, and the dietary sodium intake in CKD populations.

Keywords: Asian; blood pressure; chronic kidney disease; hypertension; kidney disease; multi-ethnicity; sodium.

PubMed Disclaimer

Conflict of interest statement

YC Chia has received honorarium and sponsorship at attend conferences and seminars from Boeringher‐Ingelheim, Pfizer, Omron, Servier and Xepa‐Sol and an investigator‐initiated research grant from Pfizer. S Siddique has received honoraria from Bayer, Novartis, Pfizer, ICI, and Servier; and travel, accommodation, and conference registration support from Hilton Pharma, Atco Pharmaceutical, Highnoon Laboratories, Horizon Pharma and ICI. CH Chen reports personal fees from Novartis, Sanofi, Daiichi Sankyo, SERVIER, Bayer, and Boehringer Ingelheim Pharmaceuticals, Inc HM Cheng received speakers honorarium and sponsorship to attend conferences and CME seminars from Eli Lilly and AstraZeneca; Pfizer Inc; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc; Daiichi Sankyo, Novartis Pharmaceuticals, Inc; SERVIER; Co., Pharmaceuticals Corporation; Sanofi; TAKEDA Pharmaceuticals International and served as an advisor or consultant for ApoDx Technology, Inc The other authors have no conflict of interest to declare.

References

    1. Kidney Disease Outcomes Quality Initiative (K/DOQI) . K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(5 Suppl 1):S1‐S290. - PubMed
    1. KDOQI . KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49(2 Suppl 2):S12‐S154. - PubMed
    1. Jinam TA, Kanzawa‐Kiriyama H, Inoue I, Tokunaga K, Omoto K, Saitou N. Unique characteristics of the Ainu population in Northern Japan. J Hum Genet. 2015;60(10):565‐571. - PubMed
    1. Subramanian S, Teo BW, Toh QC, et al. Spot urine tests in predicting 24‐hour urine sodium excretion in Asian patients. J Ren Nutr. 2013;23(6):450‐455. - PubMed
    1. Wu Y, Huxley R, Li L, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from the China national nutrition and health survey 2002. Circulation. 2008;118(25):2679‐2686. - PubMed